Jim Simons Biotechnology

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
EXEL Exelixis, Inc.	$13B	$697 Million 0.99% of portfolio	15,819,765	Q2 2025 Added 6.72%
UTHR United Therapeutics Corp	$18.4B	$609 Million 0.86% of portfolio	2,119,092	Q2 2025 Added 0.57%
CORT Corcept Therapeutics Inc	$8.05B	$460 Million 0.65% of portfolio	6,266,402	Q2 2025 Added 2.01%
VRTX Vertex Pharmaceuticals Inc	$99.4B	$447 Million 0.63% of portfolio	1,004,888	Q2 2025 Reduced 14.23%
NVO Novo Nordisk A S	$131B	$341 Million 0.48% of portfolio	4,936,796	Q2 2025 Reduced 27.63%
INCY Incyte Corp	$18.9B	$264 Million 0.37% of portfolio	3,881,932	Q2 2025 Added 4.67%
BMRN Biomarin Pharmaceutical Inc	$10.1B	$99.3 Million 0.14% of portfolio	1,806,771	Q2 2025 Added 101.7%
INVA Innoviva, Inc.	$1.36B	$95.6 Million 0.14% of portfolio	4,760,832	Q2 2025 Added 4.47%
JAZZ Jazz Pharmaceuticals PLC	$8.12B	$95.5 Million 0.14% of portfolio	900,368	Q2 2025 Reduced 13.81%
BPMC Blueprint Medicines Corp	$7.73B	$86.5 Million 0.12% of portfolio	674,500	Q2 2025 New
CPRX Catalyst Pharmaceuticals, Inc.	$2.03B	$70.6 Million 0.1% of portfolio	3,251,516	Q2 2025 Added 9.99%
ADMA Adma Biologics, Inc.	$3B	$57.3 Million 0.08% of portfolio	3,146,053	Q2 2025 Reduced 11.35%
GMAB Genmab A/S	$18.5B	$57.2 Million 0.08% of portfolio	2,766,750	Q2 2025 Added 22.3%
PTCT Ptc Therapeutics, Inc.	$4.34B	$47 Million 0.07% of portfolio	963,300	Q2 2025 Added 43.73%
TVTX Travere Therapeutics, Inc.	$1.52B	$36.9 Million 0.05% of portfolio	2,495,114	Q2 2025 Reduced 7.68%
SWTX Spring Works Therapeutics, Inc.	$2.93B	$35.7 Million 0.05% of portfolio	760,600	Q2 2025 Added 309.14%
ACAD Acadia Pharmaceuticals Inc	$3.92B	$33.4 Million 0.05% of portfolio	1,547,732	Q2 2025 Added 4.79%
INSM Insmed Inc	$19.6B	$31.1 Million 0.04% of portfolio	308,687	Q2 2025 New
TECH Bio Techne Corp	$2.02B	$30.4 Million 0.04% of portfolio	590,700	Q2 2025 Added 309.07%
HRMY Harmony Biosciences Holdings, Inc.	$1.9B	$29.4 Million 0.04% of portfolio	929,471	Q2 2025 Added 10.6%
MRNA Moderna, Inc.	$9.78B	$27.7 Million 0.04% of portfolio	1,003,900	Q2 2025 Reduced 26.19%
REGN Regeneron Pharmaceuticals, Inc.	$62.8B	$23.7 Million 0.03% of portfolio	45,062	Q2 2025 Reduced 42.89%
LEGN Legend Biotech Corp	$5.77B	$23.3 Million 0.03% of portfolio	656,300	Q2 2025 Reduced 7.68%
BCRX Biocryst Pharmaceuticals Inc	$1.43B	$22.6 Million 0.03% of portfolio	2,526,734	Q2 2025 Added 317.49%
MIRM Mirum Pharmaceuticals, Inc.	$2.73B	$20.2 Million 0.03% of portfolio	396,348	Q2 2025 Added 110.26%
RYTM Rhythm Pharmaceuticals, Inc.	$5.32B	$19.9 Million 0.03% of portfolio	314,893	Q2 2025 Added 2,131.38%
HALO Halozyme Therapeutics, Inc.	$10.6B	$17.6 Million 0.02% of portfolio	338,609	Q2 2025 Added 182.15%
VCYT Veracyte, Inc.	$2.28B	$16.5 Million 0.02% of portfolio	610,400	Q2 2025 Reduced 26.63%
VNDA Vanda Pharmaceuticals Inc.	$248M	$16.3 Million 0.02% of portfolio	3,447,460	Q2 2025 Reduced 3.34%
AKBA Akebia Therapeutics, Inc.	$524M	$15.3 Million 0.02% of portfolio	4,194,427	Q2 2025 Added 4.71%
AXSM Axsome Therapeutics, Inc.	$5B	$14.5 Million 0.02% of portfolio	138,700	Q2 2025 Added 3.2%
VRNA Verona Pharma PLC	$6.48B	$13.9 Million 0.02% of portfolio	147,400	Q2 2025 Added 48.89%
GLPG Galapagos Nv	$2.12B	$13 Million 0.02% of portfolio	464,700	Q2 2025 Added 40.48%
MDXG Mimedx Group, Inc.	$792M	$12.9 Million 0.02% of portfolio	2,107,777	Q2 2025 Added 9.2%
KRYS Krystal Biotech, Inc.	$3.95B	$12.3 Million 0.02% of portfolio	89,800	Q2 2025 Added 701.79%
VERV Verve Therapeutics, Inc.	$667M	$11.8 Million 0.02% of portfolio	1,047,600	Q2 2025 Added 479.42%
FOLD Amicus Therapeutics, Inc.	$2.24B	$11.5 Million 0.02% of portfolio	2,013,593	Q2 2025 Added 28.91%
ABCL Ab Cellera Biologics Inc.	$1.3B	$11.3 Million 0.02% of portfolio	3,307,429	Q2 2025 Added 14.28%
IONS Ionis Pharmaceuticals Inc	$8.68B	$10.7 Million 0.02% of portfolio	270,714	Q2 2025 Added 76.34%
SRPT Sarepta Therapeutics, Inc.	$1.49B	$10.7 Million 0.02% of portfolio	624,478	Q2 2025 New
BBIO Bridge Bio Pharma, Inc.	$7.59B	$10.6 Million 0.02% of portfolio	245,946	Q2 2025 New
SRRK Scholar Rock Holding Corp	$1.68B	$10.3 Million 0.01% of portfolio	291,200	Q2 2025 Reduced 8.25%
SAGE Sage Therapeutics, Inc.	$516M	$10.2 Million 0.01% of portfolio	1,113,400	Q2 2025 Added 44.65%
MRVI Maravai Lifesciences Holdings, Inc.	$370M	$10.1 Million 0.01% of portfolio	4,186,189	Q2 2025 Added 1.84%
AUPH Aurinia Pharmaceuticals Inc.	$1.75B	$9.81 Million 0.01% of portfolio	1,157,800	Q2 2025 Added 23.35%
XERS Xeris Biopharma Holdings, Inc.	$999M	$9.6 Million 0.01% of portfolio	2,055,340	Q2 2025 Reduced 4.96%
PTGX Protagonist Therapeutics, Inc	$2.87B	$9.57 Million 0.01% of portfolio	173,134	Q2 2025 Reduced 46.49%
RVMD Revolution Medicines, Inc.	$3.84B	$8.96 Million 0.01% of portfolio	243,504	Q2 2025 Added 70.52%
ARVN Arvinas, Inc.	$405M	$8.94 Million 0.01% of portfolio	1,214,355	Q2 2025 Added 817.88%
PCVX Vaxcyte, Inc.	$1.83B	$8.75 Million 0.01% of portfolio	269,077	Q2 2025 Added 37.09%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account